Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences reported weak Q1 FY26 results with revenue from operations falling about 22% to ₹28,066.5 lakh from ₹35,884.7 lakh a year ago. The company swung from a small profit of ₹296.9 lakh to a net loss of ₹6,323.1 lakh, translating to a loss per share of ₹2.82 versus earnings of ₹0.13. Total expenses rose about 6% to ₹37,777.6 lakh even as sales shrank, sharply compressing margins. More importantly, the board approved the sale of its entire active pharmaceutical ingredients and formulations business to Ceph Lifesciences as a slump sale for ₹1,270 crore, along with the menthol business assets for ₹20 crore, subject to closing adjustments. The board also fixed the 30th AGM for September 29, 2025, appointed P. Chadha & Associates as secretarial auditors for five years, re-appointed the cost auditor, and approved adoption of new Articles of Association.
The quarterly loss and steep revenue decline are negative, but the ₹1,270 crore business sale represents a major corporate event that could significantly reshape the company. Shareholders should watch the deal closure timeline, use of sale proceeds, and any post-sale business plans, as this will likely be the key driver of stock price action in the near term.